Possible involvement of IκB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor κB ligand

Journal of Bone and Mineral Research

Volumn 17, Issue 4, 2002, Pages 612-621

  Yamamoto, Aiichiro ^a   Miyazaki, Tsuyoshi ^a   Kadono, Yuho ^a   Takayanagi, Hiroshi ^a   Miura, Toshiki ^a   Nishina, Hiroshi ^b   Katada, Toshiaki ^b   Wakabayashi, Kenji ^c   Oda, Hiromi ^a   Nakamura, Kozo ^a   Tanaka, Sakae ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

Adenovirus vectors; c jun N terminal kinase; Nuclear factor B; Osteoclastogenesis; RAW264.7 cells

Indexed keywords

ADENOVIRUS VECTOR; I KAPPA B KINASE; I KAPPA B KINASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG; CARRIER PROTEIN; CHUK PROTEIN, MOUSE; IKBKB PROTEIN, MOUSE; IKBKE PROTEIN, MOUSE; MAP2K7 PROTEIN, MOUSE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STRESS ACTIVATED PROTEIN KINASE; TNFRSF11A PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE RESPONSE; GENE OVEREXPRESSION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; ADENOVIRUS; ANIMAL; CELL CULTURE; DOMINANT GENE; ENZYME ACTIVATION; GENETICS; METABOLISM; MOUSE STRAIN; PHYSIOLOGY; STEM CELL;

ADENOVIRIDAE; ANIMALS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; ENZYME ACTIVATION; GENES, DOMINANT; I-KAPPA B KINASE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE KINASE 7; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED STRAINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; OSTEOCLASTS; PROTEIN-SERINE-THREONINE KINASES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; STEM CELLS;

EID: 0036006406     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2002.17.4.612     Document Type: Article

References (51)

1. Modulation of osteoclast differentiation by local factors
2. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
3. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
4. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
5. A novel molecular mechanism modulating osteoclast differentiation and function
6. Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development
7. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
8. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
9. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
10. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
11. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
12. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
13. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
14. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase
15. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif
16. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily
17. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
18. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice
19. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2
20. Requirement for NF-kappaB in osteoclast and B-cell development
21. Bone and haematopoietic defects in mice lacking c-fos
22. Pleiotropic effects of a null mutation in the c-fos proto-oncogene
23. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling
24. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation
25. Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation
26. IkappaB kinase: Beginning, not the end
27. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation
28. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses
29. Regulation of inducible gene expression by the transcription factor NF-kappaB
30. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene
31. IKK1-deficient mice exhibit abnormal development of skin and skeleton
32. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis
33. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice
34. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
35. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL)
36. A simplified system for generating recombinant adenoviruses
37. A simple and efficient method for purification of infectious recombinant adenovirus
38. Modulation of osteoclast function by adenovirus vector-induced epidermal growth factor receptor
39. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development
40. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts
41. In vitro and in vivo suppression of osteoclast function by adenovirus vector-induced csk gene
42. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts
43. RANK is essential for osteoclast and lymph node development
44. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function
45. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
46. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor
47. Signal transduction by the JNK group of MAP kinases
48. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation
49. Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2
50. A role for TGFbeta(1) in osteoclast differentiation and survival
51. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappaB ligand and macrophage-colony- stimulating factor